4-(2-bromoacetyl)benzonitrile | CAS:20099-89-2

We serve 4-(2-bromoacetyl)benzonitrile CAS:20099-89-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-(2-bromoacetyl)benzonitrile

Chemical Name:4-(2-bromoacetyl)benzonitrile
CAS.NO:20099-89-2
Synonyms:4-(2-bromoacetyl)benzonitrile
2-bromo-4'-cyano-acetophenone
Benzonitrile,4-(bromoacetyl)
2-Bromo-4'-cyanoacetophenone
4-Cyanophenacyl BroMide
2-Bromo-4'-cyanoacetophenone
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 342.4±22.0 °C at 760 mmHg
Melting Point 92-96 °C(lit.)
Molecular Formula C9H6BrNO
Molecular Weight 224.054
Flash Point 160.9±22.3 °C
 
Specification:
Appearance:Off-white crystalls
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Isavuconazole



Contact us for information like 4-(2-bromoacetyl)benzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Bromo-4′-cyanoacetophenone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Cyanophenacyl BroMide Use and application,4-Cyanophenacyl BroMide technical grade,usp/ep/jp grade.


Related News: It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.3-Fluoro-2-methylpyridine manufacturer It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.6-Hydroxy-5-nitro-2-picoline supplier It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.2,5-Dibromo-3-nitropyridine vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).